Kane Biotech (CVE:KNE) Hits New 52-Week Low – Time to Sell?

Shares of Kane Biotech Inc. (CVE:KNE) hit a new 52-week low on Thursday . The stock traded as low as C$0.09 and last traded at C$0.09, with a volume of 11000 shares trading hands. The stock had previously closed at C$0.10.

Kane Biotech Stock Performance

The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The stock has a market cap of C$12.97 million, a PE ratio of 2.25 and a beta of 0.52. The business has a 50 day moving average price of C$0.10 and a two-hundred day moving average price of C$0.11.

Insider Activity

In other Kane Biotech news, Director Marc Edwards acquired 2,000,000 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were purchased at an average cost of C$0.10 per share, for a total transaction of C$200,000.00. Insiders own 37.21% of the company’s stock.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.